(1/5) This is perhaps not urgent but it is important. Clinical cancer research will almost certainly take a hit over the next few months. There will likely be a decrease in trial accruals and the pace of progress will slow. Our society can't afford this. @ASCO @BladderCancerUS
(2/5) However, the impact will be magnified, perhaps exponentially, by the protocol deviations and violations for missed and delayed visits leading to countless queries, EDC revisions, monitor interactions, etc.
(3/5) The burden on our research teams will increase markedly and precious time and resources will be devoted to these tasks rather than trying to accelerate clinical investigation to make up for lost time.
(4/5) As a community, we need to carefully rethink the clinical cancer research processes and procedures that contribute to data integrity and patient safety versus the tasks that might ultimately just detract from our shared goals.
(5/5) Oh...and lets think about integrating some new models as well. ascopubs.org/doi/10.1200/CC…
@DrChoueiri @ERPlimackMD @montypal @tmprowell Crowdsourcing ideas for a regulatory-compliant twitter-based approach to prospectively study the impact of #COVIDー19 on #cancer care and #cancer #clinicaltrials #covid19nCancer
De-identified data collected on shared google doc after IRB approval? How to ensure representative dataset (all patients on outpatient clinic lists for x number of providers regardless of in person or tele-visit or cancellation?)?
